Eurofins Issues EUR 500m New Euro Bond
2015年7月24日 - 2:30PM
ビジネスワイヤ(英語)
Regulatory News:
Eurofins Scientific (Paris:ERF)(ERF FP, unrated), the global
leader in bioanalytical testing, announces that it has successfully
raised EUR 500m in its latest senior unsecured Euro bond public
issuance. The bonds have a 7.5-year maturity (due 30 January 2023)
and will bear an annual rate of 3.375% (ACT/ACT). The issue was
more than 2x times over-subscribed.
Eurofins intends to use the proceeds of the issuance for general
corporate purposes, including refinancing some of its existing debt
instruments, as well as to fund any further growth opportunity
in-line with the Group’s strategy and objectives. The new bond
further improves Eurofins’ liquidity position by lengthening its
debt maturity profile.
Comment from Dr. Gilles Martin, Eurofins CEO: “I am
pleased with the result of our latest public bond issuance. In
light of the market volatility due to the developments in certain
geographies, specifically in Greece and China, we have decided to
further optimize our funding position to lengthen our financing
maturity, to secure the refinancing of our instruments coming due
in the next couple of years, and more generally to secure our
ability to respond to compelling opportunities while maintaining a
strong balance sheet structure.”
BNP Paribas, HSBC and SG CIB acted as joint bookrunners for the
transaction.
The bonds will be listed from their issue date (30 July 2015) on
the regulated market of the Luxembourg stock exchange (ISIN
XS1268496640). The bonds are not registered under the US Securities
Act of 1933 as amended (the “Securities Act”), and may not be
offered or sold in the United States (as such term is defined in
Regulation S under the Securities Act) unless registered under the
Securities Act or pursuant to an exemption from such
registration.
For more information please visit
http://www.eurofins.com or contact:
Eurofins Investor Relations Phone: + 32 2 769 7383
E-mail: ir@eurofins.com
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific is the world leader in food and
pharmaceutical products testing. It is also number one in the world
in the field of environmental laboratory services and one of the
global market leaders in agroscience, genomics, discovery
pharmacology and central laboratory services.
With over 17,000 staff in more than 200 laboratories across 36
countries, Eurofins offers a portfolio of over 130,000 reliable
analytical methods for evaluating the safety, identity,
composition, authenticity, origin and purity of biological
substances and products. The Group provides its customers with
high-quality services, accurate results in time and expert advice
by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the data
available to the Company as of the date of publication, but no
guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150723006693/en/
Eurofins Investor RelationsPhone: + 32 2 769 7383E-mail:
ir@eurofins.com
Enerplus (NYSE:ERF)
過去 株価チャート
から 6 2024 まで 7 2024
Enerplus (NYSE:ERF)
過去 株価チャート
から 7 2023 まで 7 2024